Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 23 articles: HTML format

Single Articles

May 2026
1. VERHAGEN NE, Touw DCW, van den Heuvel JJMW, van den Broek PH, et al
   Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia.
   Cancer Chemother Pharmacol. 2026;96:47.
   PubMed     Abstract available
   
   
   April 2026
2. ONG WJ
   Repurposing artesunate in acute myeloid leukemia: a pharmacokinetic rationale derived from antimalarial data.
   Cancer Chemother Pharmacol. 2026;96:43.
   PubMed    
   
   
   March 2026
3. RAHA SJ, Bhatia P, Bansal D, Trehan A, et al
   Effect of high-dose methotrexate infusion duration on 48-hour drug levels and toxicity in children with acute lymphoblastic leukaemia: a quality-of-care study.
   Cancer Chemother Pharmacol. 2026;96:24.
   PubMed     Abstract available
   
   
   January 2026
4. YANAGIMACHI M, Iwano R, Keino D, Kimizuka Y, et al
   Post-transplantation gilteritinib maintenance therapy and therapeutic drug monitoring in pediatric acute myeloid leukemia with FLT3-internal tandem duplication.
   Cancer Chemother Pharmacol. 2026;96:10.
   PubMed    
   
   
   December 2025
5. BRILLAC C, Semiond D, Oprea C, Baruchel A, et al
   Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics.
   Cancer Chemother Pharmacol. 2025;95:116.
   PubMed     Abstract available
   
   
   October 2025
6. COHEN IJ
   Comment on: Dose adjustment strategy for high dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure toxicity relationship.
   Cancer Chemother Pharmacol. 2025;95:95.
   PubMed    
   
   
   August 2025
7. SY SKB, Yang Y, Darstein C, Yoon DY, et al
   Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.
   Cancer Chemother Pharmacol. 2025;95:83.
   PubMed    
   
   
   July 2025
8. KOCH MR, Buhl Rasmussen AS, Als-Nielsen B, Duarte X, et al
   DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia.
   Cancer Chemother Pharmacol. 2025;95:76.
   PubMed     Abstract available
   
   
   April 2025
9. TANAKA Y, Ono R, Ashiarai M, Sakurai A, et al
   The evaluation of the impact of NUDT15 variants on thiopurine metabolism in Japanese children with acute lymphoblastic leukemia.
   Cancer Chemother Pharmacol. 2025;95:50.
   PubMed     Abstract available
   
   
   February 2025
10. DARSTEIN C, Yoon D, Yang Y, Kapoor S, et al
    Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia.
    Cancer Chemother Pharmacol. 2025;95:39.
    PubMed     Abstract available
    
    
    
11. OUERDANI A, Valenzuela B, Treijtel N, Haddish-Berhane N, et al
    Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).
    Cancer Chemother Pharmacol. 2025;95:38.
    PubMed     Abstract available
    
    
    
12. CAO A, Guan Y, Wang J, Li X, et al
    Dose adjustment strategy for high-dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure-toxicity relationship.
    Cancer Chemother Pharmacol. 2025;95:33.
    PubMed     Abstract available
    
    
    January 2025
13. MAHER KR, Shafer D, Schaar D, Bandyopadhyay D, et al
    A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
    Cancer Chemother Pharmacol. 2025;95:24.
    PubMed     Abstract available
    
    
    December 2024
14. MANGOURA SA, Abdel-Raheem MH, Eltyb HA, Molla MS, et al
    Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia.
    Cancer Chemother Pharmacol. 2024;95:12.
    PubMed     Abstract available
    
    
    
15. MATSUI M, Yasu T, Makimoto A, Yuza Y, et al
    Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML).
    Cancer Chemother Pharmacol. 2024;95:1.
    PubMed     Abstract available
    
    
    September 2024
16. CHRISTENSEN SR, Jensen CF, Heldrup J, Taylor Z, et al
    Hypoalbuminemia in children with acute lymphoblastic leukemia: relation to asparaginase therapy and impact on high dose methotrexate elimination.
    Cancer Chemother Pharmacol. 2024 Sep 21. doi: 10.1007/s00280-024-04713.
    PubMed     Abstract available
    
    
    July 2024
17. RAHMAYANTI SU, Amalia R, Rusdiana T
    Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients.
    Cancer Chemother Pharmacol. 2024 Jul 13. doi: 10.1007/s00280-024-04694.
    PubMed     Abstract available
    
    
    June 2024
18. CEREJA-PANTOJA KBC, de Brito Azevedo TC, Vinagre LWMS, de Moraes FCA, et al
    Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population.
    Cancer Chemother Pharmacol. 2024 Jun 18. doi: 10.1007/s00280-024-04689.
    PubMed     Abstract available
    
    
    
19. GAIETTO A, Panetta JC, Pauley JL, Relling MV, et al
    Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's Research Hospital.
    Cancer Chemother Pharmacol. 2024;93:617-625.
    PubMed     Abstract available
    
    
    May 2024
20. KOBAYASHI T, Sato H, Miura M, Fukushi Y, et al
    Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2024 May 23. doi: 10.1007/s00280-024-04673.
    PubMed     Abstract available
    
    
    March 2024
21. DILLI BATCHA JS, Gota V, Matcha S, Raju AP, et al
    Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients.
    Cancer Chemother Pharmacol. 2024 Mar 5. doi: 10.1007/s00280-024-04644.
    PubMed     Abstract available
    
    
    
22. QU W, Lu J, Ji Y, He Z, et al
    Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2024 Mar 2. doi: 10.1007/s00280-024-04642.
    PubMed     Abstract available
    
    
    February 2024
23. MARCELLETTI JF, Sikic BI
    Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.
    Cancer Chemother Pharmacol. 2024 Feb 26. doi: 10.1007/s00280-024-04656.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum